Aug 11, 2020
Eisai Announces Topline Results from Study 211 Supporting 24 mg as the Appropriate Starting Dose for LENVIMA® (lenvatinib) in Patients with Differentiated Thyroid Cancer
Jun 22, 2020
Lantheus Completes Merger with Progenics
May 21, 2020
Insomnia Data 2020: US Leads in Global Insomnia Clinical Trials, Germany Leads Major European Markets and Japan Has Top Spot in Asia
Apr 20, 2020
Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery
Mar 06, 2020
European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis
Mar 04, 2020
$770M Thyroid Cancer Drugs Market Insights, 2015-2030
Feb 25, 2020
Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meeting
Feb 10, 2020
Eisai to Present Latest on LENVIMA® (lenvatinib) at the 2020 Genitourinary Cancers Symposium
Jan 31, 2020
AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
Jan 29, 2020
CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
Jan 21, 2020
Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium
Jan 10, 2020
Technological Advancements Expand Biopharmaceuticals' Production Capabilities
Oct 04, 2019
CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery
Oct 02, 2019
CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery
Sep 26, 2019
FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks
Sep 26, 2019
Coronary Stent Patients May Not Need Long-Term Aspirin - Mount Sinai
Sep 26, 2019
Acute Bacterial Skin and Skin Structure Infections Pipeline Insight Report 2019
Sep 26, 2019
AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes
Sep 19, 2019
Eisai to Present New 12-month Safety & Effectiveness Data from Phase 3 Lemborexant SUNRISE 2 Study and New Patient and Cohabitant Insights about Insomnia and Toll on Next-Day Functioning at World Sleep Congress
Sep 09, 2019
Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO Spray (AKP01) Phase III Study Targeting Psoriasis